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Abstract
Background: The positive transcription elongation factor, P-TEFb, is required for the production of mRNAs, however the
majority of the factor is present in the 7SK snRNP where it is inactivated by HEXIM1. Expression of HIV-1 Tat leads to release
of P-TEFb and HEXIM1 from the 7SK snRNP in vivo, but the release mechanisms are unclear.
Methodology/Principal Findings: We developed an in vitro P-TEFb release assay in which the 7SK snRNP
immunoprecipitated from HeLa cell lysates using antibodies to LARP7 was incubated with potential release factors. We
found that P-TEFb was directly released from the 7SK snRNP by HIV-1 Tat or the P-TEFb binding region of the cellular
activator Brd4. Glycerol gradient sedimentation analysis was used to demonstrate that the same Brd4 protein transfected
into HeLa cells caused the release of P-TEFb and HEXIM1 from the 7SK snRNP in vivo. Although HEXIM1 binds tightly to 7SK
RNA in vitro, release of P-TEFb from the 7SK snRNP is accompanied by the loss of HEXIM1. Using a chemical modification
method, we determined that concomitant with the release of HEXIM1, 7SK underwent a major conformational change that
blocks re-association of HEXIM1.
Conclusions/Significance: Given that promoter proximally paused polymerases are present on most human genes,
understanding how activators recruit P-TEFb to those genes is critical. Our findings reveal that the two tested activators can
extract P-TEFb from the 7SK snRNP. Importantly, we found that after P-TEFb is extracted a dramatic conformational change
occurred in 7SK concomitant with the ejection of HEXIM1. Based on our findings, we hypothesize that reincorporation of
HEXIM1 into the 7SK snRNP is likely the regulated step of reassembly of the 7SK snRNP containing P-TEFb.
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Introduction
Transcription elongation by RNA polymerase II (RNAPII) is a
highly regulated process resulting from the concerted effort of both
negative and positive elongation factors. After initiation engaged
RNAPII molecules come under the control of negative factors
including NELF and DSIF that limit the elongation potential of
the polymerases and trap them in promoter proximal positions
[1,2,3]. These polymerases are poised for release into productive
elongation that ultimately generates mRNAs. The positive
transcription elongation factor, P-TEFb, is a cyclin dependent
kinase that phosphorylates the negative factors and RNAPII
leading to the transition into productive elongation [4,5]. It is clear
that P-TEFb plays a key role in the regulation of gene expression
because a number of genome wide studies have determined that
many genes in Drosophila and most genes in mammals are
occupied by poised polymerases [6,7,8,9,10,11].
The kinase activity of P-TEFb is required for the generation of
mRNAs; however, the majority of P-TEFb is sequestered within
the 7SK snRNP where it is inactivated through association with
HEXIM1 or HEXIM2 proteins [12,13,14,15]. A mechanism must
exist to extract the kinase from this inhibitory complex and direct
the function of P-TEFb to specific genes. Release of P-TEFb from
the 7SK snRNP could occur through post-translational modifica-
tion of P-TEFb or components of the 7SK snRNP. One study
showed that dephosphorylation of the T-loop of P-TEFb by PP1a
and PP2B results in its release from the 7SK snRNP [16].
Similarly, activation of the PI3K/Akt pathway through treatment
of cells with HMBA results in the phosphorylation of the cyclin T1
binding region of HEXIM1 and leads to the global release of P-
TEFb in vivo [17]. Finally, an analysis of active P-TEFb in the cell
showed that free low molecular weight P-TEFb is acetylated, while
P-TEFb bound to the 7SK snRNP is not, suggesting that
acetylation could cause release of P-TEFb from the 7SK snRNP
[18]. In addition to post-translational modifications, there is
evidence that cellular proteins recruit P-TEFb to sites of active
transcription. These include the p65/RELA subunit of NF-kB
[19], CIITA [20,21], Myc [22,23], MyoD [24,25], the androgen
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main containing protein Brd4 [29,30]. However, it is not known if
any of these enzymatic modifications or protein interactions
liberates P-TEFb directly from the 7SK snRNP.
At least four viral proteins have been shown to recruit P-TEFb
to their promoters through an interaction with cyclin T1. These
include EBV E2, HSV VP16, HTLV Tax and HIV-1 Tat
[31,32,33,34]. Early work on the functional domains of Tat
showed that a cysteine rich region is required for Tat transactiva-
tion [35,36]. It was originally thought that this region was
important for Tat dimerization, but it is now known that it is the
P-TEFb binding domain [34,37,38]. The ability of Tat to bind to
the TAR element through its basic RNA binding domain is also
important for viral replication, because loss of this region results in
a significant reduction in HIV Tat transactivation [36,39]. Also of
interest, the bulge sequence that Tat binds to in TAR (AUCUG) is
repeated 3 times in the first 100 bases of 7SK RNA and seems
unlikely to be a mere coincidence considering the fact that Tat has
a greater affinity for 7SK than TAR in vitro [40]. It has been
shown that Tat can compete for HEXIM1 binding to P-TEFb and
that the cysteine rich P-TEFb binding region of Tat is required for
this to occur in vitro and in vivo [40,41]. Although details of the
interaction between Tat and P-TEFb have been recently revealed
by structural studies [38], it is not known if Tat can extract P-
TEFb directly from the 7SK snRNP, or if this release is mediated
by other proteins.
Since HIV Tat is capable of recruiting P-TEFb to a specific
genomic location and viral proteins typically mimic the function of
cellular proteins, it seems likely that endogenous proteins perform
a similar function in recruiting P-TEFb to specific sites of
transcription. One potential candidate is bromodomain-contain-
ing protein 4 (Brd4). Brd4 has been shown to interact with many
different chromatin and transcription related proteins by binding
to acetylated lysines, and most importantly its C-terminal helical
region binds directly to cyclin T1 of P-TEFb [42,43]. In fact, most
of the P-TEFb that is not in the 7SK snRNP is found complexed
with Brd4 when the proteins are extracted from nuclei at high salt
and then the salt is removed [29]. Recent evidence also shows that
Brd4, P-TEFb, and HEXIM1 localize to nuclear speckles and this
may represent a region of P-TEFb activity or a switch between
inactive and active P-TEFb [44]. There is also evidence that Brd4
and P-TEFb appear simultaneously at sites of activation [30,45];
however, the direct role that Brd4 plays in this process is not fully
understood. Because Brd4 associates with a large fraction of P-
TEFb and also binds to active chromatin, it is possible that it is
part of a general mechanism for functional recruitment of P-
TEFb.
The 7SK snRNA plays a critical role in the regulation of P-
TEFb. Its discovery as a major structural component of a P-TEFb
inhibitory complex was novel [46,47]. Further characterization of
the regions of 7SK required for P-TEFb inhibition were
performed and it was found that the 1–100 region of 7SK is
bound specifically by HEXIM1 and that the 39 stem loop is bound
to cyclin T1 [13,48]. Additionally, HEXIM1 photo-crosslinks
specifically to U30 of 7SK further underscoring the importance of
the 1–100 region in P-TEFb inhibition [49]. The protein
composition of the 7SK snRNP is dynamic; however, the La
related protein LARP7 is constitutively associated with 7SK
[50,51,52,53]. 7SK was found to form multiple RNPs with
hnRNPA1, A2/B1, R and Q along with RNA Helicase A [52,54].
The authors of these studies speculated that hnRNP proteins are
important for releasing P-TEFb from the 7SK snRNP by
competing with HEXIM1 for 7SK binding. This might be
mediated by hnRNP binding to a hairpin loop in the middle of
7SK, which when deleted prevents the release of cyclin T1 from
exogenously expressed RNAs [52]. HEXIM1 has been shown to
be a promiscuous double stranded RNA binding protein and binds
to 7SK in vitro even in the absence of P-TEFb [55], so it is odd
that HEXIM1 leaves the 7SK snRNP when P-TEFb is released in
vivo. It is possible that HEXIM is displaced by the binding of
hnRNP proteins that occurs upon P-TEFb release [51,52,54].
Results
Release of P-TEFb from the 7SK snRNP by HIV Tat in vitro
Overexpression of Tat in vivo results in the loss of P-TEFb from
the 7SK snRNP in the absence of any other HIV proteins, RNA
or DNA and in vitro Tat can bind to 7SK RNA and compete with
HEXIM1 for binding [40]. However, the ability of Tat to directly
extract P-TEFb from the 7SK snRNP has not been explored. To
test this, Tat was expressed and purified from E. coli. The 7SK
snRNP was then isolated from HeLa cell lysates using affinity
purified antibodies to LARP7 covalently attached to paramagnetic
beads. The isolated complexes were washed, aliquoted, and
recombinant protein was then incubated with the 7SK snRNP for
15 minutes before the beads were concentrated and analyzed by
Western blot for LARP7 as a control for loading and for Cdk9 to
detect release of P-TEFb. As a positive control, RNase A was
added to one reaction. Degradation of 7SK destroys the link
between LARP7 and P-TEFb and as expected RNase caused
essentially all Cdk9 to be released from the complex (Figure 1A).
Addition of 10, 30, 100, or 300 ng of Tat for 15 minutes resulted
in the graded release of P-TEFb from the 7SK snRNP (Figure 1A).
The kinetics of Tat release was also analyzed by exposure of the
7SK snRNP to 100 ng of Tat for 3, 10, or 30 minutes. More P-
TEFb was released as exposure time increased. Evidently, Tat can
cause the release of P-TEFb directly from the 7SK snRNP in the
absence of soluble cellular factors.
The effect of the mutation of the P-TEFb binding or RNA
binding domains of Tat on P-TEFb release was also determined.
The first 48 amino acids of Tat forms extensive contacts with P-
TEFb by directly interacting with mainly cyclin T1 and with two
Zn atoms coordinated by the complex [34,38]. The remainder of
the 86 amino acid protein is basic and interacts with TAR RNA
[56]. Both domains are required for recruitment of P-TEFb to
TAR and for Tat transactivation in vivo. Of interest, the bulge
sequence that Tat binds to in TAR (AUCUG) is repeated 3 times
in the first 100 bases of 7SK RNA. It was hypothesized that, in
addition to the ability of Tat to bind to P-TEFb, a competition
with HEXIM1 for binding to 7SK may also be important for Tat
mediated P-TEFb release [40]. To determine the effect of the loss
of the P-TEFb binding region, cysteine 22 that is critical for Zn
coordination was mutated to glycine (Tat C22G). An RNA
binding mutant was generated by changing two arginines that are
essential for RNA binding region to alanines (Tat R52/53A).
The effect of the loss of the RNA binding activity of Tat on P-
TEFb release was tested by titrating Tat R52/53A into reactions
containing the 7SK snRNP. Although addition of increasing
amounts of the RNA binding mutant resulted in a graded loss of
Cdk9 from the 7SK snRNP, the relative amount of release was less
than that caused by wild type Tat (Figure 1B). The same kinetic
experiment as before was performed and a similar, although
slower loss of Cdk9 was observed (Figure 1B). The role of the P-
TEFb binding domain of Tat in P-TEFb release was then
explored. Addition of increasing amounts of Tat C22G or
incubation of the 7SK snRNP with 100 ng of Tat C22G for 30
minutes abrogated the P-TEFb release activity seen with the
wildtype protein indicating that the P-TEFb binding region is
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of Tat was still intact in this mutant, this experiment also shows
that the RNA binding region is not sufficient to release P-TEFb
from the 7SK snRNP. The P-TEFb release experiments were
repeated a number of times and the results quantitated. The
average percent of P-TEFb remaining in the complex after
treatment with wildtype and mutant Tats is plotted in Figure 1D.
It is clear that the P-TEFb binding domain of Tat is required for
release of P-TEFb from the 7SK snRNP and that the RNA
binding domain plays a lesser, but not insignificant role in the
release.
Because the preceding results suggested that the RNA binding
region may play role in P-TEFb release from the 7SK snRNP and
because Tat binds preferentially to 7SK RNA over TAR RNA in
an in vitro assay [40], we tested the effect of adding RNAs to the
release assay. This was done by pre-incubating 100 ng of Tat with
increasing amounts of HIV TAR or 7SK RNA for 15 minutes
before the 7SK snRNP was added to these reactions. Interestingly,
TAR RNA had no effect on the ability of Tat to release P-TEFb;
however, 7SK RNA inhibited it, again indicating that Tat binding
to 7SK RNA may be important for its ability to release P-TEFb
and confirming that it has a greater affinity for 7SK than TAR
(Figure 1E). To determine the effect of the loss of the RNA binding
domain on P-TEFb release, the same experiment was performed
except this time Tat R52/53A was used. In contrast to wildtype
Tat, release of P-TEFb by Tat R52/53A was not inhibited by the
presence of 7SK RNA (Figure 1F). These results suggest that Tat
binding to 7SK snRNA may play role in P-TEFb release from the
7SK snRNP, but the RNA binding region is neither essential nor
alone sufficient to cause release.
Release of P-TEFb from the 7SK snRNP by the C-terminal
region of Brd4
Because the viral protein Tat was able to release P-TEFb directly
from the 7SK snRNP, we hypothesized that an endogenous cellular
protein might possess a similar activity. Brd4 was screened as a
potential P-TEFb release factor because under some extraction
conditions Brd4 is associated with the majority of non-7SK bound
P-TEFb in the cell and it has a known P-TEFb binding domain
[29,30,43]. The P-TEFb binding region was originally identified to
be in an N-terminal region containing one of the two bromo
domains [29], but this was later attributed to a cloning error [43].
The P-TEFb binding region is actually encoded by helical region 3
in the extreme C-terminal region of Brd4 [43]. Additionally, two
labs have shown that over expression of the C-terminal tail of Brd4
can inhibit Tat transactivation of the HIV LTR [42,43] and block
Figure 1. Release of P-TEFb from the 7SK snRNP by HIV Tat. A) P-TEFb release reactions were performed as described in Materials and Methods.
IndicatedamountsofTatwereincubatedfortheindicatedtimeswithimmunoprecipitated7SKsnRNPs.B)SameasinAexcepttheRNAbindingdeficient
mutant of Tat (Tat R52/53A) was used. C) Same as in A except the P-TEFb binding deficient mutant of Tat (Tat C22G) was used. D) Tat release was
quantified from three independent experiments for wild type Tat and the RNA binding mutant and two independent experiments for the P-TEFb
binding mutant. Mean values for the percent of Cdk9 left in the complex are plotted and all error bars represent standard error. E) 100 ng of Tat was
incubated with the indicated amounts of TAR or 7SK RNA before being added to the 7SK snRNP. F) Same as in E except TatR52/53A was used.
doi:10.1371/journal.pone.0012335.g001
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region (amino acids 1209–1362) and a P-TEFb binding mutant
lacking helical region 3 (1209–1362 D1329–1345) of Brd4 were
obtained from the Verdin Lab (Figure 2A). Both proteins were
cloned into pET21a with a C-terminal histidine tag and then
expressed and purified from E. coli (Figure 2B). Addition of
increasing amounts of Brd4 1209–1362 resulted in the obvious
releaseof Cdk9 from the 7SKsnRNP(Figure 2C). Kinetic release of
Cdk9 with 200 ng of Brd4 was also observed implicating Brd4 as a
cellular P-TEFb release factor. Finally, the Brd4 mutant lacking the
C-terminal helical domain 3 of Brd4 was used in the release assay
and had no effect on Cdk9 release either by titration or time course
(Figure 2D). The Brd4 release data quantified from three
independent experiments shows that the only the intact P-TEFb
binding domain of Brd4 causes a significant release of P-TEFb from
the 7SK snRNP (Figure 2E).
To determine if the P-TEFb binding domain of Brd4 would
cause the release of P-TEFb from the 7SK snRNP in vivo, HeLa
cells were transfected with plasmids that led to the expression
FLAG tagged versions of either the wildtype P-TEFb binding
domain of Brd4 (1209–1362) or the mutant domain (1209–1362
D1329–1345). Transfection efficiencies were similar for the two
proteins and greater than 50% as evidenced by immunofluores-
cence microscopy using antibodies against the FLAG epitope
(Figure 3A). High levels of both proteins were found in the nucleus
and cytoplasm (Figure 3A). Whole cell lysates were generated from
Figure 2. Release of P-TEFb from the 7SK snRNP by the P-TEFb binding domain of Brd4. A) A schematic of Brd4 constructs used. BD1,
Bromodomain 1; BD2, Bromodomain 2; ET, Extraterminal domain; H1, H2 and H3, Helical domains 1, 2 and 3. Brd4 1209–1362 contains three helical
regions, Brd4 1209–1362 D1329–1345 is missing helical region 3 which is required for P-TEFb binding. B) Recombinant protein expressed and purified
from E. coli. A contaminating band can be seen in the Brd4 mutant preparation and this was confirmed to be an E. coli protein by Western blot (data
not shown), not full length Brd4. M, Marker; 1, Brd4 1209–1362; 2, Brd4 1209–1362 D1329–1345. C) Indicated amounts of Brd4 were added into the
release reaction for the indicated times. D) Same as in C except the Brd4 mutant missing helical domain 3 was used for the reactions. E) Brd4 release
was quantified from three independent experiments. Two independent experiments were done to calculate the mean for the Brd4 helical domain 3
mutant. The y-axis is a measure of percent of Cdk9 left in the complex. All error bars represent standard error.
doi:10.1371/journal.pone.0012335.g002
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analyzed by glycerol gradient sedimentation. As expected,
Western blot analysis of LARP7 and Cdk9 from the control cell
lysate indicated that most of the P-TEFb was in the more rapidly
sedimenting 7SK snRNP (Figure 3B, frax 10–12). An identical
pattern was obtained from the Brd4D expressing cells (Figure 3B).
However, expression of Brd4 (1209–1362) had a dramatic effect in
that most of the P-TEFb was now found in slower sedimenting
fractions (Figure 3B frax 4–6). As has been found before [51],
LARP7 sedimentation was unaffected by release of P-TEFb. These
in vivo findings support the in vitro results and strongly implicate
Brd4 in the release of P-TEFb from the 7SK snRNP.
Release of P-TEFb is accompanied by a large
conformational change in 7SK RNA
Re-analysis of the original data used to characterize the structure
of 7SK revealed that 7SK may exist in more than one conformation
in the cell. Based on chemical modification and nuclease sensitivity
studies, Wassarman and Steitz created a best fit structure for 7SK
[57]. They placed uracils 28 and 30, and uracils 66 and 68, which
are in the important HEXIM binding 1–100 region of 7SK, in
double stranded regions even though these bases showed sensitivity
to the uracil modifying agent CMCT (Figure 4A, 7SK W&S).
CMCT should be able to bind to and modify any bases located in
accessible loops because CMCT is a small molecule that reacts
specifically with N-3 of uracil. Since these bases were moderately
sensitive, we hypothesized that 7SK snRNA exists in more than one
conformation in the cell. Although the 7SK snRNP inhibits the
majority of P-TEFb, a significant fraction of this complex is not
normally associated with P-TEFb [51]. This suggests that there are
at least two 7SK snRNPs, one with and the other without P-TEFb,
which may stabilize different structures of 7SK.
To determine if different structures were computationally
possible, the first 100 bases of 7SK snRNA were folded using the
RNA/DNA folding program mFold v2.3 [58]. A number of
structures were generated, but many of the structures with low
energy fell into two ensembles of similar structures. Both groups
were represented in the top two most stable structures. One was
identical to the structure described by Wassarman and Steitz
(Figure 4A, 7SK W&S, DG 240.1 kcal/mole) while the second
folded into an alternate, slightly more stable structure (Figure 4A,
7SK Alt, DG 240.4 kcal/mole). The specific alternative structure
shown is used for illustrative purposes and we do not mean to imply
that the exact structure shown in Figure 4 is present in 7SK snRNP.
Interestingly, in the alternate structures U28, U30, U66, and U68
are found in CMCT accessible loops. A mixture of the two forms
would more adequately explain the Wassarman and Steitz data.
To test if this second alternative structure of 7SK RNA was
physiologically relevant, the structure of 7SK RNA before and after
P-TEFb release by flavopiridol was probed by primer extension of
CMCT treated 7SK snRNPs. This was done by scaling up the
immunoprecipitation protocol used for the release assays to obtain
400 ng of RNA for 7SK structure analysis. Two liters of HeLa cells
were grown in spinner flasks, split in half and treated with either
DMSO carrier as a control or with flavopiridol to release P-TEFb
from the 7SK snRNP. Lysates were made, LARP7 immunoprecip-
itation was performed, isolated complexes were washed, and then
the complexes were treated with CMCT to record the structure of
7SK locked in the 7SK snRNP. The RNA was isolated and then
primer extension was performed using AMV reverse transcriptase
and a radiolabeled DNA primer to the 100–120 region or to the 70–
90 region. Modification of uracil by CMCT blocks reverse
transcription beyond the modification site and results in the
production of an RNA sensitivity ladder. The 70–90 primer was
used to obtain more band separation in the 1–50 region to better
visualize CMCT sensitivity at U28 and U30. Release of P-TEFb
from the 7SK snRNP by flavopiridol treatment of cells resulted in
significant changes in the structure of 7SK. U28, U30 (Figure 4B),
U66, and U68 (Figure 4C) all became more sensitiveto CMCT after
P-TEFb release compared with the untreated control. These results
confirm that the alternative structure is similar to the structure of the
P-TEFb-free form of 7SK RNA (Figure 4A). Additionally, in the
alternative structure, U40/U41, U53/U54, and U76 remain in
single stranded regions and their sensitivities do not change
significantly after P-TEFb release, further supporting the existence
of a conformational switch in 7SK after P-TEFb release (Figure 4C).
Figure 3. The P-TEFb binding region of Brd4 causes a release of P-TEFb from the 7SK snRNP in vivo. HeLa cells were transfected with
plasmids expressing Brd4 1209–1362 (Brd4) or mutant Brd4 1209–1362 D1329–1345 (Brd4D). A) Immunofluorescence microscopy. 48 hours after
transfection cells were fixed and stained for DNA (DAPI) or the FLAG tagged Brd4 constructs (FLAG). B) Glycerol gradient sedimentation analysis. Cell
lysates were prepared 48 hr after transfection and sedimented on 5–45% glycerol gradients as described in Materials and Methods. Western blots of
fractions were probed with antibodies to LARP7 or Cdk9 as indicated.
doi:10.1371/journal.pone.0012335.g003
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TEFb release by other agents, lysates were again made except one
was incubated with 10 mg/mL of Tat during the LARP7
immunoprecipitation. Tat was used because it can extract P-
TEFb directly from the 7SK snRNP and because U28, U30, U66,
and U68 all reside in AUCUG repeats on 7SK (Figure 4A).
Incubation of the lysate with Tat during the immunoprecipitation
caused the release of P-TEFb from the 7SK snRNP (Figure 5A).
As was observed with flavopiridol release, U28, U30, U66, and
U68 all became more sensitive after P-TEFb left the complex
(Figure 5B and 5C). To determine if Tat also caused HEXIM1 to
be released at the same time as P-TEFb in vitro, the LARP7
immunoprecipitates shown in Figure 1A were also probed for
HEXIM1. As was found for Cdk9, decreasing amounts of
HEXIM1 were found as the amount of Tat was increased
(Figure 5D). However, release of HEXIM1 did not reach the same
extent as Cdk9 suggesting that HEXIM1 release might lag the
release of P-TEFb. The results of these CMCT modification
experiments support the idea that a conformational change occurs
in the structure of 7SK RNA after P-TEFb leaves the 7SK snRNP.
The 7SK structural change data at the uracil positions are
summarized in Figure 5E. Every U residue that changed in
reactivity to CMCT upon loss of P-TEFb from the 7SK snRNP
was found in a region that changed its conformation from single to
double or from double to single stranded. All U residues that
didn’t change in reactivity upon loss of P-TEFb were found in
regions that also did not change.
Discussion
Because most human genes contain promoter proximally
paused polymerases [10,11], the goal of this study was to
understand how the factor responsible for release of these poised
polymerases into productive elongation, P-TEFb, is targeted to
specific genes. Most of the P-TEFb in the cell is bound to and
inhibited by HEXIM1 found in the 7SK snRNP [59]. We
demonstrated that two activators of transcription, HIV-1 Tat and
human Brd4, could extract P-TEFb from the 7SK snRNP in vitro
in the absence of other soluble cellular factors or enzymes. As was
found previously for Tat [40], the P-TEFb binding domain of
Brd4 was also able to cause the release of P-TEFb from the 7SK
snRNP in vivo. Finally, we were able to resolve the mystery as to
why HEXIM1 was ejected from the 7SK snRNP after release of P-
TEFb. These results provide strong evidence for the idea that
activators take the P-TEFb they need from the 7SK snRNP and
that the process is highly regulated.
Model for activator mediated release of P-TEFb from the
7SK snRNP
Based on our results here and on published studies, we propose a
more refined model for release of P-TEFb from the 7SK snRNP
(Figure 6). Tat, Brd4 or another P-TEFb extractor binds directly to
P-TEFb and removes it from the complex. This leaves HEXIM1
bound to the 7SK snRNP. In the second step, HEXIM1 is released
from the RNA and 7SK rearranges into an alternative conforma-
tion. Loss of HEXIM1 could be caused by the rearrangement of
7SK or the rearrangement could occur after HEXIM1 dissociates.
What is clear is that the equilibrium between free and RNA bound
HEXIM1liesstrongly in favor of free HEXIM1 after P-TEFb is lost
from the complex. P-TEFb has affinity for 7SK and HIV TAR
RNA [37,48] and it is possible that this helps stabilize the binding of
HEXIM1 to 7SK in the presence of P-TEFb. After P-TEFb and
HEXIM1 are released the 7SK snRNP associates with a number of
hnRNP proteins [51,52,54,60]. Presumably this further stabilizes
the P-TEFb/HEXIM-free 7SK snRNP.
Figure 4. Release of P-TEFb by flavopiridol treatment of cells causes a conformational change in 7SK snRNA. A) HIV-1 TAR RNA stem
loop: 35–61 of TAR RNA covering the Tat binding bulge (AUCUG) and the cyclin T1 binding loop (CUGGG). 7SK Alt: Predicted structure of the 1–100
region of 7SK. 7SK W&S: structure of the 1–100 region of 7SK RNA described previously [57]. The uracil residues in 7SK RNA are marked. B) and C)
CMCT reactivity was determined as described in the Materials and Methods using extension of the indicated primers. C, control cells; F, flavopiridol
treated cells; L; sequencing ladder showing the position of uracils.
doi:10.1371/journal.pone.0012335.g004
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be reversible and is likely also highly controlled. An RNA helicase
was found in a proteomic analysis of the 7SK snRNP [51,52,61]. It
does not seem to be involved in the release of P-TEFb in vitro
because ATP is not required. However, it could be involved in the
re-assembly process. The re-association of HEXIM1 with the 7SK
snRNP must be regulated because in HeLa cells 80% of HEXIM1
is free from 7SK and about half of the 7SK in the cells lacks
HEXIM1 and P-TEFb [13,14,51]. Because our in vitro release
assay does not contain excess hnRNPs and HEXIM1 dissociates
after P-TEFb is released, simply removing the hnRNPs would not
be enough to cause HEXIM1 re-association. P-TEFb is unable to
bind to HEXIM1 unless the dsRNA binding domain of HEXIM is
occupied [55]. Binding to RNA leads to a conformational change
in HEXIM1 that allows P-TEFb to bind [55]. Therefore, the most
likely step to regulate in the re-assembly of the inactive P-TEFb/
HEXIM1 7SK snRNP is the binding of HEXIM1. This could be
controlled by regulating the conformation of 7SK or by post
translational modification of HEXIM1. Phosphorylation of
HEXIM1 has been demonstrated to block binding to RNA [17],
but it is not clear if this is the major mechanism for controlling
reassembly of the snRNP.
A key feature of our model is the conformational rearrangement
of 7SK. In the absence of a crystal structure, the exact
conformation(s) of 7SK in snRNPs can only be approximated by
the available methods. For our study we chose chemical
modification by CMCT because it offered a direct test of the
environment around U30 that is known to be in the close
proximity to bound HEXIM1 [49]. Use of the small chemical
modification reagent also circumvented the issues of limited
accessibility to protein bound regions when large nucleases are
used to probe RNA structure. We found clear evidence of a
change in the HEXIM1 binding region from double to single
stranded character when P-TEFb was released from the 7SK
snRNP. Although the proposed alternative structure (see Fig. 4) fits
our data, as described earlier, we are not proposing that the exact
alternative structure shown is that which is found in vivo. In a
detailed examination of 7SK RNA throughout evolution Marz et
al. proposed an alternative structure for 7SK [62]. That structure
differs from both the Wassarman and Steitz structure and our
alternative structure in that it contains a short stem (M1) that
forms between the 59 end of 7SK and a region just upstream from
the final stem loop about 300 nucleotides downstream. The M1
stem is picked up by mFold, but only when the entire 7SK
sequence is input. However, the Marz structure more closely
matches the Wassarman and Steitz structure in the HEXIM1
binding region except that U30 (but not U28, U66 and U68) is
opposite a very short stem loop and is unpaired in the Marz
structure.
The 7SK conservation study identified three regions that could
form alternative pairings with the M2 stem [62], therefore, a
rearrangement in this region could act as a trigger by disrupting
the structure at the base of the large stem loop to which HEXIM1
binds leading to a conformational change of the HEXIM1 binding
Figure 5. P-TEFb release by HIV Tat causes a conformational change in 7SK snRNA and release of HEXIM1 from the complex.
A) Western analysis of P-TEFb release from the 7SK snRNP after co-incubation of Tat. LARP7 and Cdk9 were analyzed by Western. I, Input; C, Control; T,
Tat treated; Bound, bound to the beads; FT, flowthrough from the beads. B) and C) CMCT reactivity was determined as described in the Materials and
Methods using extension of the indicated primers. D) Western blot of the Tat treated 7SK snRNP probed for Cdk9 and HEXIM1. Indicated amounts of
Tat were added to the 7SK snRNP. E) Graphical summary of the 7SK conformational change data. Bases in single stranded regions are boxed in black
and bases in double stranded regions are unboxed. An asterisk denotes a change in CMCT reactivity and a minus sign indicates no change.
doi:10.1371/journal.pone.0012335.g005
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in this region was seen to change slightly during Tat mediated P-
TEFb release (see Fig. 5). LARP7 would be a prime candidate for
regulating this process. By analogy to the properties of La, the La
domain in the N-terminus of the protein is almost certainly
involved in association of LARP7 with the 39 end of 7SK [63].
The hypothesized M1 loop [62] would bring the 39 and 59 ends of
7SK into close proximity of each other and another RNA binding
domain present in the C-terminal region of LARP7 could be
involved in stabilizing or destabilizing the M1 loop or one
particular arrangement of the M2 stem.
Role of the RNA binding domain of Tat
When HIV infects a cell it not only takes over P-TEFb through
association with Tat, but also takes over the control of P-TEFb by
the 7SK snRNP. The RNA binding domain of Tat is required for
efficient transactivation in vivo [36] and was originally thought to
be utilized just in recruiting P-TEFb to TAR element in the
nascent HIV transcript. Early models had Tat binding to TAR
and then recruiting P-TEFb [34,64,65,66]. Now we know that Tat
can take P-TEFb directly from the 7SK snRNP in the absence of
TAR or other viral proteins and that the TatNP-TEFb complex is
what is recruited to TAR [40]. Several pieces of evidence point
toward a role of the RNA binding domain of Tat in the release of
P-TEFb from the 7SK snRNP. First, it binds better to 7SK RNA
than to TAR, and in a defined in vitro system with just 7SK and
HEXIM1, Tat can displace HEXIM1 [40]. This may involve one
or more of the three AUCUG sequences found in 7SK that are
identical to the sequence in TAR that is essential for Tat binding
to TAR. An AUCUG sequence is found in a conserved location in
almost all putative 7SK sequences found across all species with a
7SK homologue suggesting that it is involved in a critical function
of 7SK [62]. Second, we showed here that a Tat mutation that
abrogated RNA binding slowed P-TEFb release and, importantly,
addition of excess of 7SK RNA to release reactions with wildtype
Tat blocked the ability of Tat to release P-TEFb. The RNA
binding domain may play a non-essential, but potentially
significant role in release of P-TEFb from the 7SK snRNP. The
P-TEFb binding region of Brd4 has not been shown to bind to
RNA, so perhaps cellular activators do not require RNA binding.
We speculate that HIV may have evolved to take over the
control of P-TEFb by events that occurred during the integration
of an early form of the virus. The human genome has thousands of
copies of 7SK pseudogenes. Perhaps a viral genome became
juxtaposed with a 7SK sequence during a particular integration
event. The virus might have found it advantageous for persistence
to have the HEXIM1-mediated repressive function of a 7SK
sequence keeping the virus in an inactive state. The virus then
could have created Tat by modifying a HEXIM protein so that it
eliminated the P-TEFb inhibitory domain. According to this idea,
the HIV 59 UTR maintained HEXIM binding properties to help
maintain latency, but with Tat had a way to activate the LTR to
extremely high levels under appropriate cellular conditions.
During this evolutionary process Tat had to deal with not only
the 7SK like sequence in the LTR, but also with the cellular 7SK
snRNP. The end product is a very finely tuned system using
cellular mechanisms controlling P-TEFb to the advantage of the
virus. A second driving force likely used during evolution was the
effect that Tat had on blocking other activators ability to recruit P-
TEFb. Tat competes with the co-activator CIITA for binding to P-
TEFb and this leads to down regulation of MHC class II genes
during infection [20]; a clear advantage for the virus. Also Tat and
Brd4 have been shown to compete for P-TEFb and this could have
global effects on gene expression [42,43]. Attesting to the
Figure 6. Model of P-TEFb and HEXIM1 release from the 7SK snRNP. P-TEFb is directly extracted from the 7SK snRNP by Tat or Brd4. This
leads to the loss of P-TEFb, a destabilization of the 7SK structure resulting in a conformational change in the RNA that causes HEXIM1 to be released
from the 7SK snRNP. hnRNP proteins then bind to the region of RNA unmasked by the loss of HEXIM1.
doi:10.1371/journal.pone.0012335.g006
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utilize the only known activator (Tat) that is targeted to a specific
gene through RNA.
Significance for regulation of gene expression
A large body of evidence points to the P-TEFb dependent step in
transcription as one of the most highly utilized in regulating gene
expression. About 80% of human genes and a large fraction of
Drosophila genes have RNA polymerase II molecules poised in
promoter proximal positions ready for P-TEFb to release them into
productive elongation that ultimately leads to the generation of
mature mRNAs [6,10,11]. Also the expression of essentially all
genes has been shown to require P-TEFb [11,67]. It is no wonder
that most P-TEFb is carefully tied up in the 7SK snRNP. Globally
releasing it could catastrophically affect the pattern of genes
expressed by inappropriately activating most genes. The biochem-
ical properties of the 7SK snRNP are highly suited for a function in
which P-TEFb is released only near genes that should be expressed.
First, unlike all other snRNPs the 7SK snRNP is completely
extracted by low salt conditions from mild detergent treated nuclei
[14]. This demonstrates that it is not tightly associated with any
nuclear structures and is, therefore, free to diffuse around the
nucleus. This property allows the potentially dangerous kinase
activity of the factor to be nearby any gene, but held in check by
HEXIM1. All that is needed is a mechanism to extract the P-TEFb
and keep itontaskatspecific genes,and wehave demonstratedhere
that such a mechanism exists. Although Tat directs extracted P-
TEFb to the HIV LTR, Brd4 extraction of P-TEFb from the 7SK
snRNP provides a generalmechanism for recruitment of P-TEFbto
active chromatin. Besides Brd4, many other activators and more
recently the ELL elongation complex [68] have been shown to
associate with P-TEFb on active genes. Myc, a known transcription
activator, was not able to release P-TEFb in this assay (data not
shown); however, it may function with other protein complexes. A
similar interaction has been described for the recruitment of P-
TEFb through the association of p65 with Brd4 [69]. It remains to
be determined how many cellular factors can extract P-TEFb from
the 7SK snRNP, but it is clear that once it is extracted it has a
number of interactions that could keep it localized to the
appropriate genes. Although recent data has suggested that post-
translational modification of the components of the 7SK snRNP,
such as P-TEFb acetylation [18], HEXIM phosphorylation [17], or
P-TEFb dephosphorylation [16] cause the release of P-TEFb from
the 7SK snRNP, these modifications had no effect on P-TEFb
release in our in vitro assay (data not shown). These modifications
could have significance in the context of the nuclear milieu.
Our understanding of how P-TEFb activity is directed to
specific genes will benefit from a number of possible avenues of
future research. One concerns the re-sequestration of P-TEFb
after its job is complete on any particular gene. Perhaps there is a
sequential process by which P-TEFb is obligatorily returned to the
7SK snRNP at the end of each transcription cycle. Alternatively, if
active genes are looped or clustered then it is possible that P-TEFb
is allowed to function on the same gene again or on other active
genes before it is inactivated. Support for such regional
localization of P-TEFb was recently provided by the Rice lab
who found that P-TEFb, HEXIM1 and Brd4 co-localized to
nuclear speckles [44]. As discussed above the mechanism of
HEXIM1 and P-TEFb re-entry into the 7SK snRNP and the
requisite change in the conformation of the RNA deserves further
study. As discussed earlier potential regulators of this process
include other components of the 7SK snRNP. LARP7 is always
associated with at least the 39 end of 7SK and the methyl
phosphate capping enzyme, MePCE, modifies the 59 end of 7SK.
By analogy to the founding member of the La family of related
proteins [63,70,71,72,73], post-translational modifications of
LARP7 may result in a reduced affinity the protein for regions
of 7SK. Finally, it is known that after P-TEFb and HEXIM leave
in vivo that hnRNP proteins along with an RNA helicase bind to
the 7SK snRNP [51,52]. The hnRNP proteins may serve to
protect 7SK and stabilize the HEXIM unbound state, while the
activity of the helicase may be regulated and activated to convert
7SK back to the HEXIM accessible conformation.
Materials and Methods
Expression and Purification of Recombinant Proteins
HIV Tat mutants were cloned into pET21a (Novagene) E. coli
expression vectors with histidine tags. E. coli BL21 star (DE3) cells
were transformed with the pET21a clone, used to inoculate 2 liters
of LB, gown to an OD600 of 0.5 and then expression was induced
with IPTG overnight at 18uC. Cells were harvested, washed, and
then lysed by sonication. Sonicated lysates were cleared by
centrifugation at 200 k 6g in a Beckmann Ultracentrifuge for 45
minutes. Nickel resin (Invitrogen) was then added to the cleared
lysates and the protein was bound to the resin while rotating at
4uC for 1 hr. The resin was washed and the protein was eluted by
addition of imidizole to the nickel resin. The elution was then
cleared by centrifugation to remove any precipitated proteins and
loaded onto the FPLC. Both mutant Tat proteins are positively
charged, so they were purified by FPLC after binding to a Mono S
column. The protein was then eluted over a salt gradient and
purity was assessed by silver stain.
Purification of the Brd4 proteins was similar, but because both
proteins were charge neutral, neither bound to Mono S or Mono
Q. Flowthroughs from the Mono S and Mono Q were dialyzed
against PBS for 24 hr at 4uC to remove imidizole and detergents
from the protein buffers. Purity of the proteins was determined by
SDS PAGE followed by silver staining.
Release Assay
For the release assays, 2 L of HeLa cells (National Cell Culture
Center) were cultured in spinner flasks. Cells were washed and
then lysed in Lysis Buffer (10 mM HEPES, 150 mM NaCl, 2 mM
MgCl2, 10 mM KCl, 0.5% NP240, 0.5 mM EDTA, 1 mM
DTT, 0.1% PMSF, and 1 U/mL Roche EDTA free complete
protease inhibitor cocktail) for 10 minutes with intermittent
vortexing. Lysates were cleared in a Beckmann ultracentrifuge at
200 k 6 g for 1 hr. After centrifugation, the lipid layer was
discarded and the supernatant was saved and frozen in aliquots at
280uC for later use. The M-270 Epoxy Dynabeads used in this
assay were prepared the night before. 2610
8 (100 mL) beads were
washed 2 times in PBS, then rotated for 10 minutes at room
temperature in PBS, and finally washed again in PBS. Beads were
then resuspended in 50 mg of affinity purified LARP7 antibody
and 1 M ammonium sulfate and incubated overnight (16 hr) at
37uC in a PCR tube. After incubation, the beads were washed 4
times in PBS containing 0.5% BSA. After washing, the beads were
resuspended in 300 ml of HeLa lysate (one confluent T-150) and
incubated at 4uC for 2 hr in a PCR tube. After immunoprecip-
itation, the beads were washed once in Lysis Buffer, resuspended
in 200 mL PBS containing 0.5% BSA, and then 1610
7 (10 mL)
beads were aliquotted into microfuge tubes. At this point, potential
releasing agents were added to the beads. For the release control,
4 mg of RNase A was added to one aliquot of beads. Beads were
incubated for 15 minutes, unless otherwise noted, with gentle
resuspension every 3 minutes to keep the beads suspended during
the release reactions. Reactions were then washed twice with wash
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resolved by 9% SDS-PAGE.
Western Analysis
After transfer to nitrocellulose, the membranes were cut and
incubated in 0.1% Tween 20, 16PBS and 3% milk overnight at
4uC with the appropriate primary antibody. Membranes were
then washed 3 times in 0.1% Tween 20, 16PBS and incubated
with horseradish peroxidase-conjugated secondary antibody
(Sigma). The membranes were then treated with Super Signal
Dura West Extended Duration Substrate (Pierce) and imaged
using a cooled charge-coupled camera (UVP). The antibodies used
for Western analysis were: sheep anti-cyclin T1 (Millipore 06-
1289), rabbit anti-Cdk9 (sc-8338; Santa Cruz Biotechnology),
affinity-purified sheep anti-HEXIM1 (Millipore 06-1291), and
affinity-purified sheep anti-LARP7 [51].
Chemical Modification of 7SK RNA
For chemical modification of the 7SK snRNP, complexes were
isolated similarly to the release assay except New England Biolabs
paramagnetic protein G beads were used for the isolation. 400 mLo f
beads were bound to 50 mg of antibody overnight at 4uC, washed,
and then split inhalf and incubated with 800 mLo fHe Lal y sa t e .A ft e r
immunoprecipitation, the beads were washed 4 times with 1 mL of
wash buffer. The isolated and washed complexes were then
resuspended in 200 mL of N-Cyclohexyl-N-(b-[N-methylmorpholi-
no]ethyl)carbodiimide p-toluenesulfonate (CMCT) modification
buffer which consisted of BMK buffer (80 mM potassium borate
pH 8.1, 60 mM KCl, 2 mM MgCl2,a n d3mg/mlC M C T( S i g m a ) )
and incubated at room temperature with rotation for 15 minutes.
The CMCT stock buffer was 42 mg/mL CMCT in BMK buffer.
CMCT modification reactions were then stopped by addition of
300 mL stop buffer (0.3 M sodium acetate, 0.2 M PIPESpH 6.5, and
5 mM EDTA) and placed on ice for 3 minutes. The 500 mLo f
CMCT modified beads were then transferred to 2 mL microfuge
tubes and 1 mL of Trizol was added. To that, 200 mL of chloroform
was added and then the tubes were vortexed for 20 seconds. The
emulsions were incubated for 3 minutes at room temperature and
then spun down at 14 k rpm for 20 minutes at 4uCi na
microcentrifuge. After the spin, 1.1 mL of the aqueous phase was
added to 900 mL of isopropanol, mixed gently, and incubated at
room temperature for 10 minutes to precipitate the RNA. The RNA
was then spun down at 14 k rpm for 25 minutes, the supernatant was
removed with a pulled glass Pasteur pipette and then the RNA was
washed with 300 mL of 80% EtOH. Finally, the supernatant was
again removed with a pulled glass Pasteur pipette, the pellets were air
dried and then resuspended in 20 mL ddH2O. A sample of the RNA
was analyzed by 6% TBE urea acrylamide gel electrophoresis and
samples were normalized for 7SK RNA content.
In vitro Transcription of 7SK RNA
The 7SK RNA sequence was cloned into pCR2.1 (Invitrogen).
This plasmid was then used as a template in a PCR reaction to
generate the 7SK sequence from a T7 promoter containing primer
and a reverse primer. 1 mg of PCR product was then used in an in
vitro transcription reaction with recombinant T7 RNA polymer-
ase (Stratagene) according to the manufacturer’s instructions.
Quality of the in vitro transcribed RNA was determined by
resolving the RNA on a 6% TBE urea acrylamide gel.
Hybridization and Primer Extension Reactions
To map the first 100 bases of 7SK and determine the structure
of 7SK RNA, HPLC purified antisense DNA primers were
ordered from IDT (100–120R: AGGGACGCACATGGAGC-
GGT, 70–90R: GGGGACACCCGCCTAGCCAG) and radio-
actively end labeled with c2
32P-ATP using T4 PNK. For reverse
transcription, primers were hybridized to either 100 ng of in vitro
transcribed 7SK RNA to generate the Sanger sequencing ladder,
or to 100 ng of the CMCT modified RNA extracted from in vivo
isolated RNP complexes. Reactions were hybridized to 200
femtomoles of radiolabeled primer at 80uC for 10 minutes in
hybridization buffer (40 mM HEPES pH 7.6, 5 mM boric acid,
100 mM KCl, 20 mg/mL BSA, and 0.5 U RNaseOUT) and then
at 42uC for 15 minutes in a thermal cycler. Extension was initiated
by the addition of extension buffer (50 mM Tris pH 8.4, 9 mM
MgCl2, 10 mM DTT, 20 mg/mL BSA, 100 mM KCl, 1 U AMV
reverse transcriptase, and 0.5 U RNaseOUT), and dNTP (1 mM
final concentration) or sequencing mix (2.5 mM dTTP, dGTP,
dCTP, 1.9 mM dATP, and 0.6 mM ddATP final concentration).
Primer extension was run for 1 hr in a thermal cycler at a constant
42uC. 4 mg of RNase A was added to the reactions and incubated
for 15 minutes at 42uC because the DNA and RNA form a very
strong hybrid which complicates gel analysis. Reactions were then
suspended in a total volume of 100 mLo fH 2O containing 20 mgo f
yeast tRNA carrier. 100 mL of phenol:chloroform:isoamyl alcohol
(25:24:1 v/v) was added and the samples were vortexed for 15
seconds. The samples were spun down at full speed in a
microcentrifuge for 5 minutes at room temperature. 100 mLo f
the aqueous phase was then combined with 4 mL 5 M NaCl (to a
final concentration of 200 mM) mixed, and then 200 mL of 100%
EtOH was added to initiate nucleic acid precipitation. The DNA/
RNA was then precipitated at 220uC for 30 minutes. After
incubation, the DNA/RNA was spun down at full speed in a
microcentrifuge for 15 minutes at 4uC. The DNA/RNA pellets
were washed with 80% EtOH, spun down at full speed for 5
minutes, air dried, and resuspended in 8 mL urea loading buffer.
Radiolabled DNA was resolved on a 10% TBE urea acrylamide
gel, dried, exposed for 24 hr to a phosphoimager screen, and then
imaged with a Fuji-Film FLA 7000 phosphoimager.
Glycerol gradient analysis
HeLa cells were grown to 90% confluence in three 150 mm
diameter, Nunclon Surface petri dishes (Nunc 168381). One
coverslip was placed in each flask to check transfection efficiency
by immunofluorescence microscopy. Cells were then mock
transfected or transfected with a pcDNA3 vector expressing either
Brd4 (1209–1362) or Brd4 (1209–1362 D1329–1345) using
Lipofectamine 2000 (Invitrogen 11668). Cells were scraped in
medium 48 hours post-transfection, spun down at 2000 rpm and
then lysed for 10 min on ice in 300 mM KCl, 2 mM MgCL2,
50 mM HEPES (pH 7.6), 0.1 mM EDTA, 1 mM DTT, 1/1000
PMSF saturated in isopropanol, 16EDTA-free complete protease
inhibitor cocktail (Roche) and 0.5% Triton 62100. The lysates
were clarified by centrifugation for 5 min. at 13 k rpm in a
microcentrifuge prior to fractionation on 5 ml, 5–45% glycerol
gradients in the same buffer conditions used during lysis, except
that Triton 62100 and the protease inhibitor cocktail were
omitted. Gradients were run at 45 k rpm for 16 hr in a Beckman
SW-55Ti rotor before being separated into 16 fractions. Gradient
fractions were resolved by 9% SDS-PAGE followed by transfer to
0.45 mm nitrocellulose membranes.
Immunofluorescence microscopy
Cells were fixed in 3.7% formaldehyde in PBS, permeabilized in
0.5% Triton62100 in TBS and then blocked in 2% BSA in TBS.
Coverslips were stained with 1/200 dilution of anti-Flag antibody
produced in rabbit (Sigma-F7425) in TBS for 1 hr at 37uC
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goat anti-rabbit IgG (invitrogen-A11034) in TBS for one more
hour at 37uC. Slides were imaged using a Leica DMR microscope
with appropriate filters.
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